Terumo Neuro: Aiming for #1 in Neurovascular

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s rebranding, plans for growth and becoming the market leader in neuroendovascular technologies in an interview with SmartTRAK. Listen to the video below to find out more, including how Terumo plans to innovate and take share via new disease states and markets in addition to its core neurovascular markets (ischemic, hemorrhagic and access).

Click to watch the video here. A link to download the complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

Interview Topics by Timecode:

00:23 Carsten’s background. Rebranding MicroVention to Terumo Neuro and the relationship with Terumo Group. Using the name change to signal that Terumo is moving into other disease states and markets (chronic subdural hematoma (CSDH), hydrocephalus, neuro-oncology) in addition to its core markets (hemorrhagic, ischemic stroke and access).

03:50 Becoming the leading neurovascular company via a broader role in neuro with new products/markets. Technologies under development for the endovascular treatment of CSDH, hydrocephalus, neuro-oncology. Carsten’s view of AI and robotics in neurovascular, the use of sensors. Terumo is exclusively focused on neuroendovascular procedures.

10:14 Carsten’s main priorities as president and CEO in 2025. Working with Terumo’s leadership to focus on what ideas will move the company forward and executing on those ideas. Taking market share and growing faster than the market. Terumo’s strengths that give it an edge in the market.

13:14 The fastest growing segments in the overall neuro market, the company’s investment in R&D and a greater focus on business development activities (e.g., opportunities, acquisitions, early stage investments)

14:47 Terumo’s broad portfolio, the SOFIA 088, how it’s performing in the market, innovation in mechanical thrombectomy and potential areas of interest in product development.

18:36 Status and plans for the WEB, its value proposition vs emerging intrasaccular devices and celebrating WEB’s 15th anniversary. Percent of hemorrhagic business that is WEB vs FRED X, FRED X ‘s status, growth and market share in the US. Doubling investments in clinical trials and the status of the RESTORE and Complex Aneurysm Registry.

27:15 Terumo’s projected growth in 2025, countries where Terumo is seeing the fastest growth, the impact of value-based procurement in China. The potential impact of tariffs and sourcing materials. Terumo Neuro’s investment in the US and California. Innovating to treat more patients and partnering with physicians.

Click here to download and read the complete transcript of the "Terumo Neuro: Aiming for #1 in Neurovascular" interview with Carsten Schroeder, president and CEO of Terumo Neuro, conducted by Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies.